Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
In vitro inhibition of HIV-1 by Met-SDF-1 beta alone or in combination with antiretroviral drugs
Autore:
Rusconi, S; Merill, DP; Catamancio, SL; Citterio, P; Bulgheroni, E; Croce, F; Chou, TC; Yang, OO; Herrmann, SH; Galli, M; Hirsch, MS;
Indirizzi:
Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA MassachusettsGen Hosp Boston MA USA 02114 fect Dis, Boston, MA 02114 USA Harvard Univ, Sch Med, Boston, MA USA Harvard Univ Boston MA USAHarvard Univ, Sch Med, Boston, MA USA Univ Milan, Osped Luigi Sacco, Ist Malattie Infett & Trop, Milan, Italy Univ Milan Milan Italy Sacco, Ist Malattie Infett & Trop, Milan, Italy Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA Mem Sloan Kettering Canc Ctr New York NY USA 10021 New York, NY 10021 USA Genet Inst, Cambridge, MA 02140 USA Genet Inst Cambridge MA USA 02140Genet Inst, Cambridge, MA 02140 USA
Titolo Testata:
ANTIVIRAL THERAPY
fascicolo: 3, volume: 5, anno: 2000,
pagine: 199 - 204
SICI:
1359-6535(200009)5:3<199:IVIOHB>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR CXCR4; RECOMBINANT SOLUBLE CD4; SMALL-MOLECULE INHIBITOR; DOWN-MODULATION; TROPIC HIV-1; ENTRY; INFECTION; CORECEPTOR; MACROPHAGES;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Rusconi, S Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA Massachusetts Gen Hosp Boston MA USA 02114 oston, MA 02114 USA
Citazione:
S. Rusconi et al., "In vitro inhibition of HIV-1 by Met-SDF-1 beta alone or in combination with antiretroviral drugs", ANTIVIR TH, 5(3), 2000, pp. 199-204

Abstract

Compounds that can block the CXCR4 chemokine receptor are a promising new class of antiretroviral agents. In these experiments we studied the effect of a modified form of the native stromal cell-derived factor-1 (SDF-1), Met-SDF-1 beta. The in vitro susceptibility of two different CXCR4-tropic HIV-1 strains was determined. Antiviral effect was assessed by the reduction ofp24 antigen production in PHA-stimulated peripheral blood mononuclear cells with exposure to the modified SDF-1 molecule. The 50% inhibitory concentrations (IC50) were derived from six separate experiments. The IC50 against the two HIV-1 isolates was in 1.0-2.8 mug/ml range for Met-SDF-1 beta. Met-SDF-1 beta showed synergy to additivity with either zidovudine or nelfinavir at IC75, IC90 and IC95. Additivity was seen when Met-SDF-1 beta was combined with efavirenz. No cellular toxicity was observed at the highest concentrations when these agents were used either singly or in combination. This compound is a promising new candidate in a receptor-based approach to HIV-1infection in conjunction with currently available combination antiretroviral drug therapies.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 23:47:57